BioCentury
ARTICLE | Company News

GlaxoSmithKline sales and marketing update

September 1, 2014 7:00 AM UTC

GlaxoSmithKline launched Tanzeum albiglutide in the U.S. to treat Type II diabetes as monotherapy or as add-on therapy. The wholesale acquisition cost of 4 injections of 30 or 50 mg once-weekly Tanze...